Fig. 6

TRAIL-R2 is functionally upregulated upon exposure to olaparib and leads to increased caspase cascade activation. a Representative image demonstrated NK cell lysing olaparib-treated BRCA WT target cell by activating caspase cascade and a representative graph demonstrating increased caspase activation as identified by a FLICA reagent following administration of olaparib in both BRCA WT and BRCA mutant cells. b Expression of TRAIL-R2 on 22RV1 was upregulated from 36% (MFI 104) to 65% (MFI 151) following a 48 h treatment with olaparib. c BRCA mutant prostate carcinoma (22RV1) cell lysis with or without olaparib (ola) and KillerTRAIL antibodies after 36 h. d Expression of TRAIL-R2 on DU145 was upregulated from 3% (MFI 28) to 96% (MFI 103). e BRCA WT prostate carcinoma (DU145) cell lysis with or without olaparib and KillerTRAIL antibodies after 36 h. f Expression of TRAIL-R2 on Wild-Type and TRAIL-R2 CRISPR knockout DU145 cells. g Functional confirmation of the involvement of TRAIL-R2. DU145 and TRAIL-R2 CRISPR knockout DU145 cell lysis with or without olaparib and NK cells after 36 h. Depicted is fold-change in percent lysis. These experiments were performed twice with similar results. p < 0.05*, p < 0.01**, p < 0.001***, p < 0.0001***